| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 13.7019 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 13.7019. The average price that 2413.T shares were previous bought at was JPY 14.5405. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in 2413.T has fallen by JPY 6,355 (USD $41) compared to the previous valuation of M3, Inc. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.2039 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.2039. The average price that 4151.T shares were previous bought at was JPY 15.766. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 19,771 (USD $126) compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 28.6499 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 28.6499. The average price that 4502.T shares were previous bought at was JPY 28.7761. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in 4502.T has fallen by JPY 56 (USD $0) compared to the previous valuation of Takeda Pharmaceutical Company Limited |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.1145 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.1145. The average price that 4507.T shares were previous bought at was JPY 16.9224. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in 4507.T has fallen by JPY 12,515 (USD $80) compared to the previous valuation of Shionogi & Co., Ltd. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 52.085 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 52.085. The average price that 4519.T shares were previous bought at was JPY 47.1026. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in 4519.T has fallen by JPY 8,237 (USD $53) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 30.0751 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 30.0751. The average price that 4523.T shares were previous bought at was JPY 30.4104. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 19,780 (USD $126) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 14.9321 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 14.9321. The average price that 4543.T shares were previous bought at was JPY 16.4615. The current market price is -9.3% lower than average price they were purchased at. The value of the holding in 4543.T has fallen by JPY 1,289 (USD $8) compared to the previous valuation of Terumo Corporation |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 21.8246 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 21.8246. The average price that 4568.T shares were previous bought at was JPY 24.016. The current market price is -9.1% lower than average price they were purchased at. The value of the holding in 4568.T has fallen by JPY 70,713 (USD $451) compared to the previous valuation of Daiichi Sankyo Company, Limited |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 59.5303 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 59.5303. The average price that 4578.T shares were previous bought at was JPY 53.8172. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 7,155 (USD $46) compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.41364 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.41364. The average price that 6869.T shares were previous bought at was JPY 12.1551. The current market price is -22.6% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 12,965 (USD $83) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.8935 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.8935. The average price that 7733.T shares were previous bought at was JPY 12.683. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in 7733.T has fallen by JPY 6,617 (USD $42) compared to the previous valuation of Olympus Corporation |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 151.558 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 151.558. The average price that 7741.T shares were previous bought at was JPY 145.43. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in 7741.T has increased by JPY 12,984 (USD $83) compared to the previous valuation of HOYA Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 79.7608 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 79.7608. The average price that ALC.SW shares were previous bought at was CHF 77.8813. The current market price is 2.4% higher than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 31,835 (USD $39,502) compared to the previous valuation of however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 404.46 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 404.46. The average price that ALNY shares were previous bought at was USD 420.837. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in ALNY has fallen by USD 114,455 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 315.38 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 315.38. The average price that AMGN shares were previous bought at was USD 303.193. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 56,319 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 896.667 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 896.667. The average price that ARGX.BR shares were previous bought at was EUR 848.918. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 14,290 (USD $16,617) compared to the previous valuation of Argenx SE however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 18.26 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 18.26. The average price that BAX shares were previous bought at was USD 19.5282. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in BAX has increased by USD 1,553 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 42.6272 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 42.6272. The average price that BAYN.DE shares were previous bought at was EUR 32.1111. The current market price is 32.7% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 8,070 (USD $9,384) compared to the previous valuation of Bayer AG however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 177.55 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 177.55. The average price that BIIB shares were previous bought at was USD 174.078. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 15,617 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 121.659 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 121.659. The average price that BIM.PA shares were previous bought at was EUR 126.982. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 582 (USD $677) compared to the previous valuation of BioMerieux however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 51.21 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 51.21. The average price that BMY shares were previous bought at was USD 47.4544. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 70,582 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 92.7 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 92.7. The average price that BSX shares were previous bought at was USD 100.9. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 5,752 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 92.7 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 92.7. The average price that BSX shares were previous bought at was USD 100.9. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 5,752 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 262.6 | USD 0 | The current share valuation price of CI based on adjusted close was USD 262.6. The average price that CI shares were previous bought at was USD 289.268. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in CI has fallen by USD 4,050 compared to the previous valuation of Cigna Corp |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 38.67 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 38.67. The average price that CNC shares were previous bought at was USD 38.4552. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in CNC has increased by USD 55,473 compared to the previous valuation of Concurrent Technologies Plc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| COH.AX - | HOLD | 0 @ AUD 174.062 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 174.062. The average price that COH.AX shares were previous bought at was AUD 185.335. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in COH.AX has fallen by AUD 125,016 (USD $83,023) compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 80.74 | USD 0 | The current share valuation price of COO based on adjusted close was USD 80.74. The average price that COO shares were previous bought at was USD 75.7632. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in COO has increased by USD 42,258 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 340.79 | USD 0 | The current share valuation price of COR based on adjusted close was USD 340.79. The average price that COR shares were previous bought at was USD 322.921. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in COR has increased by USD 130,001 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 120.539 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 120.539. The average price that CSL.AX shares were previous bought at was AUD 120.199. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in CSL.AX has fallen by AUD 6,848 (USD $4,548) compared to the previous valuation of |
| CVS - CVS Health Corp | HOLD | 0 @ USD 78.97 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 78.97. The average price that CVS shares were previous bought at was USD 71.3419. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in CVS has increased by USD 55,446 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 33.292 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.292. The average price that DEMANT.CO shares were previous bought at was DKK 35.6299. The current market price is -6.6% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 8,161 (USD $1,271) compared to the previous valuation of however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 179.51 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 179.51. The average price that DGX shares were previous bought at was USD 181.236. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in DGX has fallen by USD 253 compared to the previous valuation of Quest Diagnostics Incorporated |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.42 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.42. The average price that DHR shares were previous bought at was USD 210.396. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 338,289 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.42 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.42. The average price that DHR shares were previous bought at was USD 210.396. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 338,289 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 243.9 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 243.9. The average price that DIM.PA shares were previous bought at was EUR 221.89. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in DIM.PA has increased by EUR 2,678 (USD $3,114) compared to the previous valuation of Sartorius Stedim Biotech however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 67.56 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 67.56. The average price that DXCM shares were previous bought at was USD 69.2306. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 14,462 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 331.797 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 331.797. The average price that EL.PA shares were previous bought at was EUR 343.118. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 26,391 (USD $30,688) compared to the previous valuation of EssilorLuxottica SA |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 66.8949 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 66.8949. The average price that ERF.PA shares were previous bought at was EUR 69.1842. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 3,889 (USD $4,522) compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 83.92 | USD 0 | The current share valuation price of EW based on adjusted close was USD 83.92. The average price that EW shares were previous bought at was USD 79.2564. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in EW has increased by USD 61,787 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 46.4981 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 46.4981. The average price that FME.DE shares were previous bought at was EUR 50.5005. The current market price is -7.9% lower than average price they were purchased at. The value of the holding in FME.DE has increased by EUR 4,705 (USD $5,471) compared to the previous valuation of Fresenius Medical Care AG however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| FPH.NZ - | HOLD | 0 @ NZD 21.8948 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 21.8948. The average price that FPH.NZ shares were previous bought at was NZD 21.1892. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 1,439 (USD $832) compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 55.9282 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 55.9282. The average price that FRE.DE shares were previous bought at was EUR 52.6051. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 12,461 (USD $14,490) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 209.057 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 209.057. The average price that GALD.SW shares were previous bought at was CHF 184.919. The current market price is 13.1% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 36,202 (USD $44,921) compared to the previous valuation of however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 84.47 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 84.47. The average price that GEHC shares were previous bought at was USD 76.0568. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in GEHC has increased by USD 14,091 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 310.398 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 310.398. The average price that GMAB.CO shares were previous bought at was DKK 283.346. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 33,243 (USD $5,176) compared to the previous valuation of |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.4627 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.4627. The average price that GRF.MC shares were previous bought at was EUR 13.1145. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 201 (USD $234) compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.0235 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.0235. The average price that GSK.L shares were previous bought at was GBP 23.2775. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 66,928 (USD $89,038) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 20.3803 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.3803. The average price that HIK.L shares were previous bought at was GBP 22.8502. The current market price is -10.8% lower than average price they were purchased at. The value of the holding in HIK.L has fallen by GBP 3,246 (USD $4,318) compared to the previous valuation of |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.74476 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.74476. The average price that HLN.L shares were previous bought at was GBP 4.88723. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 10,766 (USD $14,323) compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.83 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.83. The average price that HOLX shares were previous bought at was USD 70.1915. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 4,720 compared to the previous valuation of Hologic Inc |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 256.66 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 256.66. The average price that HUM shares were previous bought at was USD 266.026. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 110,703 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 256.66 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 256.66. The average price that HUM shares were previous bought at was USD 266.026. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 110,703 compared to the previous valuation of Humana Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 701.83 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 701.83. The average price that IDXX shares were previous bought at was USD 620.213. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in IDXX has increased by USD 42,395 compared to the previous valuation of IDEXX Laboratories Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 134.91 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 134.91. The average price that ILMN shares were previous bought at was USD 105.712. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 9,027 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 95.17 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 95.17. The average price that INCY shares were previous bought at was USD 103.645. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in INCY has increased by USD 124 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 189.85 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 189.85. The average price that INSM shares were previous bought at was USD 202.139. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in INSM has fallen by USD 49,455 compared to the previous valuation of Insmed Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 141.45 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 141.45. The average price that IPN.PA shares were previous bought at was EUR 136.113. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 4,629 (USD $5,383) compared to the previous valuation of Ipsen SA |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 261.99 | USD 0 | The current share valuation price of LH based on adjusted close was USD 261.99. The average price that LH shares were previous bought at was USD 262.705. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in LH has increased by USD 6,897 compared to the previous valuation of Laboratory Corporation of America Holdings however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 670.03 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 670.03. The average price that LONN.SW shares were previous bought at was CHF 677.302. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 1,670 (USD $2,072) compared to the previous valuation of |
| MCK - McKesson Corporation | HOLD | 0 @ USD 813.1 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 813.1. The average price that MCK shares were previous bought at was USD 782.733. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 285,207 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 100.77 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 100.77. The average price that MDT shares were previous bought at was USD 97.6271. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 39,512 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 135.397 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 135.397. The average price that MRK.DE shares were previous bought at was EUR 131.09. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in MRK.DE has fallen by EUR 5,045 (USD $5,866) compared to the previous valuation of Merck KGaA |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1405.85 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1405.85. The average price that MTD shares were previous bought at was USD 1462.76. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in MTD has increased by USD 81,048 compared to the previous valuation of Mettler-Toledo International Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1405.85 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1405.85. The average price that MTD shares were previous bought at was USD 1462.76. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in MTD has increased by USD 81,048 compared to the previous valuation of AMUNDI EUR GOV 710 however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 155.63 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 155.63. The average price that NBIX shares were previous bought at was USD 141.588. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 1,170 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 233.13 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 233.13. The average price that NTRA shares were previous bought at was USD 177.101. The current market price is 31.6% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 7,620 compared to the previous valuation of Natera Inc |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 71.0744 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 71.0744. The average price that ORNBV.HE shares were previous bought at was EUR 68.0558. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 1,191 (USD $1,385) compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.78 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.78. The average price that PFE shares were previous bought at was USD 24.7953. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 116,055 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 26.7766 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 26.7766. The average price that PHIA.AS shares were previous bought at was EUR 26.6135. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 4,253 (USD $4,946) compared to the previous valuation of Koninklijke Philips NV |
| PME.AX - | HOLD | 0 @ AUD 157.61 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 157.61. The average price that PME.AX shares were previous bought at was AUD 179.896. The current market price is -12.4% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 10,499 (USD $6,972) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 295.19 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 295.19. The average price that PODD shares were previous bought at was USD 332.622. The current market price is -11.3% lower than average price they were purchased at. The value of the holding in PODD has increased by USD 3,007 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 45.7531 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 45.7531. The average price that QIA.DE shares were previous bought at was EUR 45.883. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 14,601 (USD $16,978) compared to the previous valuation of QIAGEN NV |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 55.02 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 55.02. The average price that REC.MI shares were previous bought at was EUR 58.4266. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in REC.MI has fallen by EUR 4,477 (USD $5,206) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 726.21 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 726.21. The average price that REGN shares were previous bought at was USD 713.31. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 231,643 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 251.5 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 251.5. The average price that RMD shares were previous bought at was USD 255.906. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in RMD has increased by USD 20,802 compared to the previous valuation of ResMed Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 413.132 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 413.132. The average price that RO.SW shares were previous bought at was CHF 344.315. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 99,565 (USD $123,545) compared to the previous valuation of however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 401.171 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 401.171. The average price that ROG.SW shares were previous bought at was CHF 360.483. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 481,109 (USD $596,984) compared to the previous valuation of however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 38.26 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 38.26. The average price that RPRX shares were previous bought at was USD 37.0508. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 1,442 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 96.2561 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 96.2561. The average price that SAN.PA shares were previous bought at was EUR 99.0235. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in SAN.PA has fallen by EUR 29,460 (USD $34,257) compared to the previous valuation of Sanofi SA |
| SHL.AX - | HOLD | 0 @ AUD 15.2639 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.2639. The average price that SHL.AX shares were previous bought at was AUD 15.0755. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in SHL.AX has fallen by AUD 3,295 (USD $2,188) compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 50.049 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 50.049. The average price that SHL.DE shares were previous bought at was EUR 53.2688. The current market price is -6.0% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 6,424 (USD $7,470) compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 1.88477 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.88477. The average price that SIG.AX shares were previous bought at was AUD 1.89606. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 5,871 (USD $3,899) compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.6373 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.6373. The average price that SN.L shares were previous bought at was GBP 17.2329. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in SN.L has fallen by GBP 80 (USD $106) compared to the previous valuation of Smith & Nephew PLC |
| SOBI.ST - | HOLD | 0 @ SEK 35.4032 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 35.4032. The average price that SOBI.ST shares were previous bought at was SEK 33.0531. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 10,246 (USD $1,095) compared to the previous valuation of however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 81.9001 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 81.9001. The average price that SOLV shares were previous bought at was USD 73.2227. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in SOLV has increased by USD 7,076 compared to the previous valuation of Solventum Corp. however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 293.378 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 293.378. The average price that SRT3.DE shares were previous bought at was EUR 257.323. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 25,790 (USD $29,989) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| STE - STERIS plc | HOLD | 0 @ USD 258.84 | USD 0 | The current share valuation price of STE based on adjusted close was USD 258.84. The average price that STE shares were previous bought at was USD 242.811. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in STE has increased by USD 52,477 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 114.421 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 114.421. The average price that STMN.SW shares were previous bought at was CHF 121.432. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in STMN.SW has increased by CHF 8,195 (USD $10,169) compared to the previous valuation of however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| SYK - Stryker Corporation | HOLD | 0 @ USD 353.8 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 353.8. The average price that SYK shares were previous bought at was USD 370.054. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in SYK has increased by USD 73,308 compared to the previous valuation of Stryker Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 281.969 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 281.969. The average price that UCB.BR shares were previous bought at was EUR 251.702. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 6,864 (USD $7,982) compared to the previous valuation of UCB SA however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 484.86 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 484.86. The average price that UTHR shares were previous bought at was USD 425.301. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 7,914 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 229.16 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 229.16. The average price that VEEV shares were previous bought at was USD 280.462. The current market price is -18.3% lower than average price they were purchased at. The value of the holding in VEEV has fallen by USD 79,818 compared to the previous valuation of Veeva Systems Inc Class A |
| WAT - Waters Corporation | HOLD | 0 @ USD 395.82 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 395.82. The average price that WAT shares were previous bought at was USD 342.165. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 154,560 compared to the previous valuation of Waters Corporation however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 395.82 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 395.82. The average price that WAT shares were previous bought at was USD 342.165. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 154,560 compared to the previous valuation of MULETFWATIMETFP however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 266.96 | USD 0 | The current share valuation price of WST based on adjusted close was USD 266.96. The average price that WST shares were previous bought at was USD 265.179. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in WST has increased by USD 1,384 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 93.09 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 93.09. The average price that ZBH shares were previous bought at was USD 97.0535. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 3,573 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-12-10 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | SELL | -111 @ USD 468.73 | USD -52,029 | The ETF sold 111 shares of HCA on 2025-12-10. The shares were previously bought for an average price of USD 444.112. The HCA Holdings Inc shares were sold for 5.5% higher than average price of previous purchases. This sale made a profit of USD 2,733 The average price that the ETF previously sold HCA share for is USD 375.681 so the ETF has sold 111 shares on 2025-12-10 at a higher price than the previous selling average. |
| MRK - Marks Electrical Group PLC | SELL | -540 @ USD 97.62 | USD -52,715 | The ETF sold 540 shares of MRK on 2025-12-10. The shares were previously bought for an average price of USD 84.5364. The Marks Electrical Group PLC shares were sold for 15.5% higher than average price of previous purchases. This sale made a profit of USD 7,065 The average price that the ETF previously sold MRK share for is USD 81.0731 so the ETF has sold 540 shares on 2025-12-10 at a higher price than the previous selling average. |
| MRK - Merck & Company Inc | SELL | -540 @ USD 97.62 | USD -52,715 | The ETF sold 540 shares of MRK on 2025-12-10. The shares were previously bought for an average price of USD 84.5364. The Merck & Company Inc shares were sold for 15.5% higher than average price of previous purchases. This sale made a profit of USD 7,065 The average price that the ETF previously sold MRK share for is USD 81.0731 so the ETF has sold 540 shares on 2025-12-10 at a higher price than the previous selling average. |
| ISRG - Intuitive Surgical Inc | SELL | -95 @ USD 555.92 | USD -52,812 | The ETF sold 95 shares of ISRG on 2025-12-10. The shares were previously bought for an average price of USD 539.07. The Intuitive Surgical Inc shares were sold for 3.1% higher than average price of previous purchases. This sale made a profit of USD 1,601 The average price that the ETF previously sold ISRG share for is USD 529.422 so the ETF has sold 95 shares on 2025-12-10 at a higher price than the previous selling average. |
| IQV - IQVIA Holdings Inc | SELL | -239 @ USD 222.92 | USD -53,278 | The ETF sold 239 shares of IQV on 2025-12-10. The shares were previously bought for an average price of USD 197.785. The IQVIA Holdings Inc shares were sold for 12.7% higher than average price of previous purchases. This sale made a profit of USD 6,007 The average price that the ETF previously sold IQV share for is USD 192.737 so the ETF has sold 239 shares on 2025-12-10 at a higher price than the previous selling average. |
| AZN.L - AstraZeneca PLC | SELL | -296 @ GBP 180.013 | GBP -53,284 | The ETF sold 296 shares of AZN.L on 2025-12-10. The shares were previously bought for an average price of GBP 161.094. The AstraZeneca PLC shares were sold for 11.7% higher than average price of previous purchases. This sale made a profit of GBP 5,600 (USD $7,450) The average price that the ETF previously sold AZN.L share for is GBP 169.047 so the ETF has sold 296 shares on 2025-12-10 at a higher price than the previous selling average. |
| CAH - Cardinal Health Inc | SELL | -269 @ USD 198.21 | USD -53,318 | The ETF sold 269 shares of CAH on 2025-12-10. The shares were previously bought for an average price of USD 169.974. The Cardinal Health Inc shares were sold for 16.6% higher than average price of previous purchases. This sale made a profit of USD 7,595 The average price that the ETF previously sold CAH share for is USD 178.354 so the ETF has sold 269 shares on 2025-12-10 at a higher price than the previous selling average. |
| ZTS - Zoetis Inc | SELL | -452 @ USD 118.07 | USD -53,368 | The ETF sold 452 shares of ZTS on 2025-12-10. The shares were previously bought for an average price of USD 137.567. The Zoetis Inc shares were sold for -14.2% lower than average price of previous purchases. This resulted in an overall loss of USD 8,813 The average price that the ETF previously sold ZTS share for is USD 165.961 which is higher than the selling price of USD 118.07 on 2025-12-10. |
| GILD - Guild Esports Plc | SELL | -441 @ USD 121.34 | USD -53,511 | The ETF sold 441 shares of GILD on 2025-12-10. The shares were previously bought for an average price of USD 116.846. The Guild Esports Plc shares were sold for 3.8% higher than average price of previous purchases. This sale made a profit of USD 1,982 The average price that the ETF previously sold GILD share for is USD 113.075 so the ETF has sold 441 shares on 2025-12-10 at a higher price than the previous selling average. |
| COLO-B.CO - | SELL | -611 @ DKK 87.6877 | DKK -53,577 | The ETF sold 611 shares of COLO-B.CO on 2025-12-10. The shares were previously bought for an average price of DKK 91.8933. The shares were sold for -4.6% lower than average price of previous purchases. This resulted in an overall loss of DKK 2,570 (USD $400) The average price that the ETF previously sold COLO-B.CO share for is DKK 97.3572 which is higher than the selling price of DKK 87.6877 on 2025-12-10. |
| ABT - Abbott Laboratories | SELL | -438 @ USD 122.55 | USD -53,677 | The ETF sold 438 shares of ABT on 2025-12-10. The shares were previously bought for an average price of USD 131.432. The Abbott Laboratories shares were sold for -6.8% lower than average price of previous purchases. This resulted in an overall loss of USD 3,890 The average price that the ETF previously sold ABT share for is USD 133.302 which is higher than the selling price of USD 122.55 on 2025-12-10. |
| SOON.SW - | SELL | -216 @ CHF 249.05 | CHF -53,795 | The ETF sold 216 shares of SOON.SW on 2025-12-10. The shares were previously bought for an average price of CHF 272.775. The shares were sold for -8.7% lower than average price of previous purchases. This resulted in an overall loss of CHF 5,125 (USD $6,359) The average price that the ETF previously sold SOON.SW share for is CHF 300.723 which is higher than the selling price of CHF 249.05 on 2025-12-10. |
| A - Agilent Technologies Inc | SELL | -375 @ USD 143.47 | USD -53,801 | The ETF sold 375 shares of A on 2025-12-10. The shares were previously bought for an average price of USD 135.355. The Agilent Technologies Inc shares were sold for 6.0% higher than average price of previous purchases. This sale made a profit of USD 3,043 The average price that the ETF previously sold A share for is USD 136.726 so the ETF has sold 375 shares on 2025-12-10 at a higher price than the previous selling average. |
| VRTX - Vertex Pharmaceuticals Inc | SELL | -121 @ USD 444.64 | USD -53,801 | The ETF sold 121 shares of VRTX on 2025-12-10. The shares were previously bought for an average price of USD 424.634. The Vertex Pharmaceuticals Inc shares were sold for 4.7% higher than average price of previous purchases. This sale made a profit of USD 2,421 The average price that the ETF previously sold VRTX share for is USD 437.626 so the ETF has sold 121 shares on 2025-12-10 at a higher price than the previous selling average. |
| TMO - Time Out Group plc | SELL | -94 @ USD 573.81 | USD -53,938 | The ETF sold 94 shares of TMO on 2025-12-10. The shares were previously bought for an average price of USD 480.613. The Time Out Group plc shares were sold for 19.4% higher than average price of previous purchases. This sale made a profit of USD 8,761 The average price that the ETF previously sold TMO share for is USD 448.089 so the ETF has sold 94 shares on 2025-12-10 at a higher price than the previous selling average. |
| SDZ.SW - | SELL | -733 @ CHF 73.6311 | CHF -53,972 | The ETF sold 733 shares of SDZ.SW on 2025-12-10. The shares were previously bought for an average price of CHF 58.9694. The shares were sold for 24.9% higher than average price of previous purchases. This sale made a profit of CHF 10,747 (USD $13,335) The average price that the ETF previously sold SDZ.SW share for is CHF 53.6577 so the ETF has sold 733 shares on 2025-12-10 at a higher price than the previous selling average. |
| UNH - UnitedHealth Group Incorporated | SELL | -166 @ USD 328.37 | USD -54,509 | The ETF sold 166 shares of UNH on 2025-12-10. The shares were previously bought for an average price of USD 320.82. The UnitedHealth Group Incorporated shares were sold for 2.4% higher than average price of previous purchases. This sale made a profit of USD 1,253 The average price that the ETF previously sold UNH share for is USD 340.683 which is higher than the selling price of USD 328.37 on 2025-12-10. |
| ELV - Elevance Health Inc | SELL | -162 @ USD 341.04 | USD -55,248 | The ETF sold 162 shares of ELV on 2025-12-10. The shares were previously bought for an average price of USD 335.65. The Elevance Health Inc shares were sold for 1.6% higher than average price of previous purchases. This sale made a profit of USD 873 The average price that the ETF previously sold ELV share for is USD 353.317 which is higher than the selling price of USD 341.04 on 2025-12-10. |
| ELV - Elevance Health Inc | SELL | -162 @ USD 341.04 | USD -55,248 | The ETF sold 162 shares of ELV on 2025-12-10. The shares were previously bought for an average price of USD 335.65. The Elevance Health Inc shares were sold for 1.6% higher than average price of previous purchases. This sale made a profit of USD 873 The average price that the ETF previously sold ELV share for is USD 353.317 which is higher than the selling price of USD 341.04 on 2025-12-10. |
| NOVO-B.CO - Novo Nordisk A/S | SELL | -1,148 @ DKK 48.1768 | DKK -55,307 | The ETF sold 1148 shares of NOVO-B.CO on 2025-12-10. The shares were previously bought for an average price of DKK 55.194. The Novo Nordisk A/S shares were sold for -12.7% lower than average price of previous purchases. This resulted in an overall loss of DKK 8,056 (USD $1,254) The average price that the ETF previously sold NOVO-B.CO share for is DKK 62.0405 which is higher than the selling price of DKK 48.1768 on 2025-12-10. |
| 4503.T - Astellas Pharma Inc. | SELL | -4,200 @ JPY 13.2545 | JPY -55,669 | The ETF sold 4200 shares of 4503.T on 2025-12-10. The shares were previously bought for an average price of JPY 10.9602. The Astellas Pharma Inc. shares were sold for 20.9% higher than average price of previous purchases. This sale made a profit of JPY 9,636 (USD $61) The average price that the ETF previously sold 4503.T share for is JPY 11.7639 so the ETF has sold 4200 shares on 2025-12-10 at a higher price than the previous selling average. |
| BDX - Becton Dickinson and Company | SELL | -282 @ USD 198.4 | USD -55,949 | The ETF sold 282 shares of BDX on 2025-12-10. The shares were previously bought for an average price of USD 184.074. The Becton Dickinson and Company shares were sold for 7.8% higher than average price of previous purchases. This sale made a profit of USD 4,040 The average price that the ETF previously sold BDX share for is USD 185.418 so the ETF has sold 282 shares on 2025-12-10 at a higher price than the previous selling average. |
| TEVA - Teva Pharma Industries Ltd ADR | SELL | -1,885 @ USD 29.8 | USD -56,173 | The ETF sold 1885 shares of TEVA on 2025-12-10. The shares were previously bought for an average price of USD 19.6334. The Teva Pharma Industries Ltd ADR shares were sold for 51.8% higher than average price of previous purchases. This sale made a profit of USD 19,164 The average price that the ETF previously sold TEVA share for is USD 17.2156 so the ETF has sold 1885 shares on 2025-12-10 at a higher price than the previous selling average. |
| JNJ - Johnson & Johnson | SELL | -307 @ USD 206.54 | USD -63,408 | The ETF sold 307 shares of JNJ on 2025-12-10. The shares were previously bought for an average price of USD 170.33. The Johnson & Johnson shares were sold for 21.3% higher than average price of previous purchases. This sale made a profit of USD 11,116 The average price that the ETF previously sold JNJ share for is USD 162.172 so the ETF has sold 307 shares on 2025-12-10 at a higher price than the previous selling average. |
| NOVN.SW - | SELL | -500 @ CHF 131.34 | CHF -65,670 | The ETF sold 500 shares of NOVN.SW on 2025-12-10. The shares were previously bought for an average price of CHF 124.474. The shares were sold for 5.5% higher than average price of previous purchases. This sale made a profit of CHF 3,433 (USD $4,260) The average price that the ETF previously sold NOVN.SW share for is CHF 120.954 so the ETF has sold 500 shares on 2025-12-10 at a higher price than the previous selling average. |
| ABBV - AbbVie Inc | SELL | -294 @ USD 225.18 | USD -66,203 | The ETF sold 294 shares of ABBV on 2025-12-10. The shares were previously bought for an average price of USD 207.229. The AbbVie Inc shares were sold for 8.7% higher than average price of previous purchases. This sale made a profit of USD 5,278 The average price that the ETF previously sold ABBV share for is USD 196.751 so the ETF has sold 294 shares on 2025-12-10 at a higher price than the previous selling average. |
| LLY - Eli Lilly and Company | SELL | -130 @ USD 993.64 | USD -129,173 | The ETF sold 130 shares of LLY on 2025-12-10. The shares were previously bought for an average price of USD 847.853. The Eli Lilly and Company shares were sold for 17.2% higher than average price of previous purchases. This sale made a profit of USD 18,952 The average price that the ETF previously sold LLY share for is USD 785.598 so the ETF has sold 130 shares on 2025-12-10 at a higher price than the previous selling average. |